Related Experiment Videos

Dominant epitopes and synthetic peptides in myasthenia gravis

M Sela¹, S L Kirshner, Y Katz-Levy

¹Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.

Israel Journal of Medical Sciences

|January 1, 1995

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

A dual altered peptide ligand inhibits myasthenia gravis associated responses by inducing phosphorylated extracellular-regulated kinase 1,2 that upregulates CD4+CD25+Foxp3+ cells.

Scandinavian journal of immunology·2007

MHC class I expression regulates susceptibility to spontaneous autoimmune disease in (NZBxNZW)F1 mice.

Lupus·2005

Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus.

Annals of the rheumatic diseases·2005

Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.

Clinical and experimental immunology·2004

Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies.

Annals of the rheumatic diseases·2003

Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies.

Clinical and experimental immunology·2003

See all related articles